This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Neurology  • Meningitis  • Public Health, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Complicated Road Map

Kristine A. Moore, MD, MPH; Michael T. Osterholm, PhD, MPH

JAMA. 1998;279:472-473.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Although great strides have been made in decreasing and nearly eliminating the occurrence of invasive disease caused by Haemophilus influenzae type B, we have not been nearly so successful with invasive disease caused by Neisseria meningitidis . Over the past few decades, the incidence of invasive meningococcal disease in the United States has remained relatively stable, despite the availability of a quadrivalent polysaccharide vaccine.¹

Approximately 2500 cases of invasive meningococcal disease occur in the United States each year, with a case-fatality rate of 10% to 15%.² Reasons for this stable incidence of disease are complex and pose substantial public health challenges. Many different meningococcal serogroups cause invasive disease, and within serogroups new clones emerge periodically that influence disease incidence and clinical course. Among these are the ET-15 serogroup C clone, which emerged in Canada in the late 1980s³ and early . . . [Full Text of this Article]

From the Acute Disease Epidemiology Section, Minnesota Department of Health, 717 Delaware St SE, Minneapolis, MN 55440-9441.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Meningococcal Vaccination
Richard V. Lee, Andrew S. Stancioff, Thomas L. Treadwell, Kristine A. Moore, and Michael T. Osterholm
JAMA. 1998;280(6):515-516.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Efficacy of Meningococcal Vaccine and Barriers to Vaccination
Nancy Rosenstein, Orin Levine, Jeffery P. Taylor, Deborah Evans, Brian D. Plikaytis, Jay D. Wenger, and Bradley A. Perkins
JAMA. 1998;279(6):435-439.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Meningococcal Infection in College Students
Barton and Shulman
AAP Grand Rounds 1999;2:13-14.
FULL TEXT  

Meningococcal Vaccination
Lee et al.
JAMA 1998;280:515-516.
FULL TEXT